Search Result

Results for "

MDM2-p53

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (9) Autophagy (2) E1/E2/E3 Enzyme (10) Isotope-Labeled Compounds (2) MDM-2/p53 (34) PROTACs (1)
By Research Areas:	Cancer (39)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a *MDM2-p53* complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-14967

NSC 66811	MDM-2/p53	Cancer
NSC 66811 is a *MDM2-p53* inhibitor, with a K_i of 120 nM for binding to MDM2 .

HY-161039

MDM2-p53-IN-18	MDM-2/p53	Cancer
MDM2-p53-IN-18 (Compd A-7b) is a *MDM2-p53* interaction inhibitor .

HY-161041

MDM2-p53-IN-20	MDM-2/p53	Cancer
MDM2-p53-IN-20 (Compd B-11j) is a synthetic *MDM2-p53* interaction inhibitor that play an important role in cancer .

HY-161040

MDM2-p53-IN-19	Others	Cancer
MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the *MDM2-p53* interaction with anticancer activity .

HY-151172

MDM2-p53-IN-15	MDM-2/p53 Apoptosis	Cancer
MDM2-p53-IN-15 is a *MDM2-p53* inhibitor with an IC₅₀ value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .

HY-123544

RDR03871	MDM-2/p53	Cancer
RDR03871 (compound 2) is a potent dual *MDM2/MDM4* inhibitor with IC₅₀ values of 35.4 nM and 10.4 nM for MDM2-p53 and MDM4-p53, respectively .

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-12941

AM-7209	MDM-2/p53	Cancer
AM-7209 is a potent and selective *MDM2-p53* interaction inhibitor with a K_d of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC₅₀ of 1.6 nM. AM-7209 shows antitumor activities .

HY-150620

BI-0282	MDM-2/p53	Cancer
BI-0282 (Compound 1) is a potent *MDM2-p53* interaction inhibitor .

HY-149988

UNP-6457	MDM-2/p53	Cancer
UNP-6457 is a potent active *MDM2-p53* interaction inhibitor with an IC₅₀ values of 8.9 nM .

HY-18658A

Siremadlin (R Enantiomer) NVP-HDM201 (R Enantiomer); HDM201 (R Enantiomer)	Others	Others
Siremadlin R Enantiomer (NVP-HDM201 R Enantiomer) is the R enantiomer of Siremadlin. Siremadlin is a potent and highly specific *MDM-2/p53* inhibitor.

HY-18052

AM-8553	MDM-2/p53	Cancer
AM-8553 is a *MDM2/p53* inhibitor (K_D: 0.4 nM for MDM2). AM-8553 has anti-tumor activity

HY-130684

MDM2-IN-1	MDM-2/p53	Cancer
MDM2-IN-1 (Compound 30) is a synthetic **MDM2-p53 interaction (MDM2)** inhibitor and contains the trans (D-)configuration .

HY-10959

RG7112 15+ Cited Publications RO5045337	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed *MDM2-p53* inhibitor, with an IC₅₀ of 18 nM and a K_D of 11 nM for binding to MDM2 .

HY-144105

NSC405640	MDM-2/p53	Cancer
NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

HY-18331

MI-219	MDM-2/p53	Cancer
MI-219 is an antagonist for *MDM2* with a K_i of 13.3 μM. MI-219 inhibits the *MDM2-p53* interaction, inhibits thus the proliferation of FSCCL cells, with an IC₅₀ of 2.5 μM .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting *MDM2* and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-17493

MI-773 4 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
MI-773 is a potent *MDM2-p53* protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (K_d=8.2 nM). MI-773 has antitumor activity .

HY-153939S

Idasanutlin-d3-1 RG7388-d₃-1	Isotope-Labeled Compounds	Cancer
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-18986

SAR405838 2 Publications Verification MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-100765

BI-0252	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
BI-0252 is an orally active, selective *MDM2-p53* inhibitor with an IC₅₀ of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis .

HY-151169

MDM2/4-p53-IN-1	MDM-2/p53	Cancer
MDM2/4-p53-IN-1 is a potent *MDM2-p53* and MDM4-p53 inhibitor with IC₅₀ values of 35.9, 57.4 nM, respectively. MDM2/4-p53-IN-1 shows antiproliferative activity .

HY-125858

MI-1061 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-125858A

MI-1061 TFA 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 TFA is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-151171

MDM2/4-p53-IN-3	MDM-2/p53	Cancer
MDM2/4-p53-IN-3 is a *MDM2/4-p53* protein-protein interactions (PPIs) inhibitor (IC₅₀s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .

HY-18986S

SAR405838-d10 MI-77301-d₁₀	Isotope-Labeled Compounds	Cancer
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-122038

NU-8165	Others	Cancer
NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .

HY-148416

p53 Activator 7	MDM-2/p53	Cancer
p53 Activator 7 is a p53 mutation Y220C (MDM-2/p53) activator with an EC₅₀ of 104 nM. p53 Activator 7 can bind to p53 mutant and restore its ability to bind DNA (WO2022213975A1; Example B-1) . p53 Activator 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163083

JN122	MDM-2/p53 Apoptosis	Cancer
JN122, a spiroindoline-containing molecule, is a MDM2 inhibitor. JN122 Inhibits MDM2/p53 protein–protein interaction and exerts robust in vivo antitumor efficacy. JN122 has antiproliferative activity in HCT-116 cells and HEK-293 cells with IC₅₀ values of 39.6 nM and 4.28μM, respectively. JN122 can promote activation of p53 and its target genes, inhibited cell cycle progression, and induced cell apoptosis .

HY-125858B

(S,R,S)-MI-1061	Others	Others
(S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-158684

YX-02-030	PROTACs MDM-2/p53	Cancer
YX-02-030M is a PROTAC *MDM2* degrader. YX-02-030M inhibits MDM2-p53 binding and VHL-HIF1α binding with IC₅₀s of 63 nM and 1.35 μM respectively. YX-02-030M binds MDM2 and recruits the VHL E3 ubiquitin ligase to initiate MDM2 degradation, and effectively kills p53 mutant or deleted Triple-negative breast cancers (TNBC) cells. (Blue: VHL ligand; Black: linker; Pink: MDM2 inhibitor) .

HY-10029

Nutlin-3a Maximum Cited Publications 43 Publications Verification Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits *MDM2-p53*?interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53?wild-type ovarian carcinomas .

HY-10029A

(Rac)-Nutlin-3 (Rac)-Rebemadlin	MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme	Cancer
(Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). (Rac)-Nutlin-3 inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas .

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-W340839

p53-MDM2-IN-1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-W340313

p53-MDM2-IN-4	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-145670

cis,trans-Germacrone	Akt MDM-2/p53	Cancer
cis,trans-Germacrone is a isomer of Germacrone (HY-N0440). Germacrone exhibits a wide range of antitumor, antioxidant and anti-inflammatory effects. Germacrone inhibits lung cancer cell proliferation and alters the Akt/MDM2/p53. Germacrone also arrests cell cycle at G1/S phase .

HY-107466

WK298	Others	Cancer
WK298 is a potent inhibitor of the MDM2/MDMX-p53 interaction with good anti-tumor activity. WK298 can fully activate the p53 pathway by inhibiting the binding of MDM2 and MDMX to p53. The development of WK298 benefited from a deep understanding of the key elements of the p53-MDM2/MDMX interaction structure .

HY-151170

MDM2/4-p53-IN-2	MDM-2/p53 Apoptosis	Cancer
MDM2/4-p53-IN-2 (2q) is a potent dual MDM2/ MDM4 inhibitor and p53 activator with the IC₅₀ values of 70.7 nM for MDM2- p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity .

HY-149250

MDMX/MDM2-IN-2	MDM-2/p53 Apoptosis	Cancer
MDMX/MDM2-IN-2 is a potent *p53-MDM2/MDMX* dual inhibitors with K_is of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .

Cat. No.	Product Name

HY-L003

Apoptosis Compound Library	2,413 compounds
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease. MCE designs a unique collection of 2,413 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Apoptosis Compound Library

2,413 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 2,413 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L109

Protein-protein Interaction Inhibitor Library	616 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 616 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Protein-protein Interaction Inhibitor Library

616 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 616 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting *MDM2* and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701593

	MDM2 Protein, Human MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; RING-type E3 ubiquitin transferase MDM2; p53-binding protein MDM2	Human	E. coli
	MDM2 protein is a key E3 ubiquitin protein ligase that coordinates cellular processes by ubiquitinating and degrading p53/TP53 and inhibiting its tumor suppressor function. In addition to p53/TP53 regulation, MDM2 inhibits p53/TP53- and p73/TP73-mediated responses, self-ubiquitinates, and targets ARRB1 for degradation. MDM2 Protein, Human is the recombinant human-derived MDM2 protein, expressed by E. coli , with tag free. The total length of MDM2 Protein, Human is 95 a.a., with molecular weight of 11.1 kDa.

HY-P701594

	MDM2 Protein, Human (His) MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; RING-type E3 ubiquitin transferase MDM2; p53-binding protein MDM2	Human	E. coli
	MDM2 protein is a key E3 ubiquitin protein ligase that coordinates cellular processes by ubiquitinating and degrading p53/TP53 and inhibiting its tumor suppressor function. In addition to p53/TP53 regulation, MDM2 inhibits p53/TP53- and p73/TP73-mediated responses, self-ubiquitinates, and targets ARRB1 for degradation. MDM2 Protein, Human (His) is the recombinant human-derived MDM2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of MDM2 Protein, Human (His) is 95 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83705

	MDM2 Antibody (YA3442) ACTFS antibody; Double minute 2 protein antibody; E3 ubiquitin-protein ligase MDM2 antibody; Hdm 2 antibody; Hdm2 antibody; HDMX antibody; MDM 2 antibody; MDM2 antibody; MDM2 oncogene E3 ubiquitin protein ligase antibody; MDM2 p53 E3 ubiquitin protein ligase homolog antibody; MDM2 transformed 3T3 cell double minute 2 p53 binding protein (mouse) binding protein 104kDa antibody; MDM2_HUMAN antibody; MDM2BP antibody; Mouse Double Minute 2 antibody; MTBP antibody; Murine Double Minute Chromosome 2 antibody; Oncoprotein MDM2 antibody; p53 Binding Protein MDM2 antibody; p53-binding protein MDM2 antibody; Ubiquitin protein ligase E3 MDM2 antibody; Ubiquitin protein ligase E3 MDM2 antibody	WB, IHC-P, ICC/IF	Human, Monkey
	MDM2 Antibody (YA3442) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA3442), targeting MDM2, with a predicted molecular weight of 55 kDa (observed band size: 90 kDa). MDM2 Antibody (YA3442) can be used for WB, ICC/IF, IHC-P experiment in human, monkey background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: